660 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AMGN Amgen Inc. $200.81 $129.98B Sell
Article Searches
Top Analyst Reports for Bank of America, Amgen & NextEra Energy http://www.zacks.com/research-daily/379778/top-analyst-reports-for-bank-of-america-amgen-nextera-energy?cid=CS-ZC-FT-379778 Apr 12, 2019 - Top Analyst Reports for Bank of America, Amgen & NextEra Energy
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More http://www.zacks.com/stock/news/376834/biotech-stock-roundup-amgns-evenity-earns-fda-approval-deal-wins-more?cid=CS-ZC-FT-376834 Apr 10, 2019 - Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/371457/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-371457 Apr 05, 2019 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval http://www.zacks.com/stock/news/370846/pfizers-new-lung-cancer-drug-vizimpro-gets-eu-approval?cid=CS-ZC-FT-370846 Apr 04, 2019 - Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta http://www.zacks.com/stock/news/370752/novartis-resubmits-bla-to-fda-for-biosimilar-of-neulasta?cid=CS-ZC-FT-370752 Apr 04, 2019 - Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL http://www.zacks.com/stock/news/365652/biotech-stock-roundup-biib-cnat-crash-on-study-failures-lxrx-gets-crl?cid=CS-ZC-FT-365652 Mar 27, 2019 - Key highlights of the past week are multiple study failures and other pipeline updates.
Top Research Reports for Apple, Amgen & United Technologies http://www.zacks.com/research-daily/364738/top-research-reports-for-apple-amgen-united-technologies?cid=CS-ZC-FT-364738 Mar 26, 2019 - Top Research Reports for Apple, Amgen & United Technologies
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent http://www.zacks.com/stock/news/360917/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent?cid=CS-ZC-FT-360917 Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Roche Gets Approval for Label Expansion of MabThera in Europe http://www.zacks.com/stock/news/359892/roche-gets-approval-for-label-expansion-of-mabthera-in-europe?cid=CS-ZC-FT-359892 Mar 15, 2019 - Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

Pages: 123456...66

Page 1>